用短效β阻塞剂治疗的败血症患者的死亡率:随机对照试验的综合元分析
Mihai-Gabriel Alexandru1, Patrick Niewald2, Stefan Krüger2
1Department of Anaesthesiology, Intensive Care, Emergency Medicine, Transfusion Medicine and Pain Therapy, University Hospital of Bielefeld, Campus Bielefeld-Bethel, University of Bielefeld, Burgsteig 13, Haus Gilead I, 33617, Bielefeld, Germany. alexandrumihaig@yahoo.com.
Critical care (London, England)
|November 28, 2024
概括
短效β-阻塞剂没有显著影响持续性心跳动的败血症患者的短期死亡率. 需要进一步的研究来了解它们在败血症管理中的作用.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 在败血症中使用短效β-阻断剂是有争议的.
- 最近的试验为这种治疗方法提供了新的见解.
研究的目的:
- 评估短效β抑制剂对成人败血病患者死亡率的影响.
- 通过元分析来综合最近的证据.
主要方法:
- 进行了随机对照研究的元分析.
- 包括对静脉注射兰地醇或埃斯莫洛尔治疗败血症的研究.
- 主要终点是短期死亡率.
主要成果:
- 分析了7项涉及854名患者的研究.
- 短期β抑制剂没有显著影响短期或聚合死亡率.
- 根据年龄或心律没有观察到显著差异.
结论:
- 短效β阻塞剂不会降低持续性心跳动的败血症患者的短期死亡率.
- 未来的研究需要详细的血液动力学数据,以更好地评估心脏功能.
相关概念视频
Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
Depolarizing Blockers: Pharmocokinetics
308
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
308
Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
429
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
429
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
530
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
530
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707


